By Sabela Ojea


Intel on Thursday delivered a muted outlook for sales in its current quarter. Shares of the chipmaker dropped 10%, to $44.52, in after-hours trading.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on PTC Therapeutics' Translarna authorization following a re-examination procedure. Shares of the biopharmaceutical company declined 12%, to $23.50, in after-hours trading.

KLA posted a profit miss in its fiscal second quarter amid weaker demand for its products. Shares of the maker of equipment for the semiconductor industry fell 5.9%, to $603.75, in after-hours trading.


Write to Sabela Ojea at sabela.ojea@wsj.com


(END) Dow Jones Newswires

01-25-24 1844ET